Latest Articles
Emerging Trends and Treatment Strategies in Ovarian Cancer: A Comprehensive Review.
Ovarian cancer (OC) is the eighth leading cause of cancer deaths in women globally, mainly originating from epithelial cells. It is further divided into type-I and type-II based on histology, …
Published: Feb. 3, 2026, midnight
PARP-1 couples β-catenin/TCF4 signaling to epithelial-mesenchymal transition in endometriosis.
Published: Feb. 2, 2026, midnight
GSK expands cancer treatment options in India with launch of immunotherapy and PARP inhibitor - connectedtoindia.com
GSK expands cancer treatment options in India with launch of immunotherapy and PARP inhibitor connectedtoindia.com
Published: Aug. 26, 2025, 4:39 a.m.
(PDF) The PENDOR study: establishment of a panel of patient-derived tumor organoids from endometrial cancer to assess efficacy of PARP inhibitors - ResearchGate
(PDF) The PENDOR study: establishment of a panel of patient-derived tumor organoids from endometrial cancer to assess efficacy of PARP inhibitors ResearchGate
Published: Feb. 14, 2025, 3:13 a.m.
Rubraca sheds positive light for PARP inhibitors in endometrial cancer - Clinical Trials Arena
Rubraca sheds positive light for PARP inhibitors in endometrial cancer Clinical Trials Arena
Published: April 2, 2024, 7 a.m.
Link copied to clipboard!